Irritable bowel syndrome (IBS) affects a large portion of the general population. New research coordinated by Karolinska Institutet now shows a link between defective sucrase-isomaltase gene variants and IBS.
Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder. More than 10% of the population suffer from recurrent symptoms including abdominal pain, gas, diarrhea and constipation. What causes IBS is largely unknown, and this hampers the development of effective treatment for many patients.
Now an international research team led by scientists from Karolinska Institutet in Sweden have identified defective sucrase-isomaltase gene variants that increase the risk of IBS. The study is published in the scientific journal Gut.
"People with IBS often connect their symptoms to certain foods, particularly fermentable carbohydrates. We tested the hypothesis that genetic changes in the breakdown of disaccharides -- small carbohydrates from sugars and starches -- may be associated with increased risk of IBS" says corresponding author Mauro D'Amato from Karolinska Institutet.
The researchers studied DNA variants in the gene encoding the enzyme sucrase-isomaltase (SI), due to the observation that SI mutations are often found in hereditary forms of sucrose intolerance, whose main characteristics diarrhea, abdominal pain and bloating are also common in IBS.
By screening 1887 study participants from multiple centers in Sweden, Italy and US, they found that rare defective SI mutations were twice more common among IBS cases than healthy controls, and a common variant with reduced enzymatic activity was also associated with increased risk of IBS.
"A significant decrease in the enzymatic activity of sucrase-isomaltase would be compatible with poor carbohydrate digestion in the intestine, possibly leading to malabsorption and bowel symptoms" says co-senior author Hassan Naim from the University of Veterinary Medicine Hannover.
"Our results provide rationale for novel nutrigenetic studies in IBS, with potential for personalizing treatment options based on SI genotype" adds Mauro D'Amato.
Cite This Page: